{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-033066","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.138905+00:00","generated_at":"2026-06-18T00:59:59.356390+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Century Therapeutics FY2022 net loss $130.9M; cash runway extended into 2026","bullets":["Net loss of $130.9M for FY2022 vs $95.8M in FY2021; R&D expenses $97.2M (up 29%).","Cash, cash equivalents, and investments: $367.4M as of Dec 31, 2022; cash runway into 2026.","Collaboration revenue from BMS: $5.2M for FY2022.","Phase 1 ELiPSE-1 trial of CNTY-101 dosed first patient in Feb 2023; initial data by year-end 2023.","FY2023 GAAP operating expense guidance: $135M-$145M, incl. $12M-$17M stock-based comp."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-033066","json":"https://secwatch.observer/filing/0001104659-23-033066.json","markdown":"https://secwatch.observer/filing/0001104659-23-033066.md","text":"https://secwatch.observer/filing/0001104659-23-033066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923033066/0001104659-23-033066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923033066/tm239540d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:59:59.356390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16c31044ce5f112a1b4a2e4ad9ef8c705b879a4b","claim":"Century Therapeutics, Inc. reported the full-year ended December 31, 2022 results: revenue $5.2 million, net income $130.9 million. Guidance reaffirmed.","evidence_excerpt":"of $118.0 million), compared to net cash used in operations of $89.0 million for the twelve months ended December 31, 2021. · Collaboration Revenue: Collaboration revenue was $5.2 million for the twelve months ended December 31, 2022, generated through the Company’s collaboration, option and license agreement with BMS. · Research and Development (R&D) expenses :","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465923033066/0001104659-23-033066-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full-year ended December 31, 2022"},{"label":"Revenue","value":"$5.2 million"},{"label":"Net income","value":"$130.9 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}